Computing and Library Services - delivering an inspiring information environment

Brexit – What are the potential consequences for pharma patents and SPCs?

Fraser, Jamie and Stone, James (2017) Brexit – What are the potential consequences for pharma patents and SPCs? British Journal of Pharmacy, 2 (1). ISSN 2058-8356

PDF - Published Version
Available under License Creative Commons Attribution.

Download (493kB) | Preview


Brexit raises a number of difficult questions with regard to intellectual property rights in a post-Brexit world, particularly for UK based pharma companies. Whilst the position with regard to the current European patent system is unchanged, the fate of the unitary patent and the unified patent court remains uncertain. Of more immediate concern is the possible future position with respect to supplementary patent certificates. Should the UK fail to reach an agreement with the EU with respect to marketing authorisations for new pharmaceuticals then there is a real possibility that UK based pharma companies may find themselves in a position where they are unable to obtain EU-wide SPC protection.

Item Type: Article
Uncontrolled Keywords: Brexit, pharmaceutical patents, SPCs, UPCA, EPO, CJEU, Great Repeal Bill
Subjects: Q Science > Q Science (General)
Q Science > QD Chemistry
R Medicine > R Medicine (General)
R Medicine > RS Pharmacy and materia medica
Schools: School of Applied Sciences
Related URLs:
Depositing User: Megan Taylor
Date Deposited: 05 Sep 2017 08:56
Last Modified: 26 Mar 2018 17:30


Downloads per month over past year

Repository Staff Only: item control page

View Item View Item

University of Huddersfield, Queensgate, Huddersfield, HD1 3DH Copyright and Disclaimer All rights reserved ©